Does Extended Interval Dosing Natalizumab Preserve Effectiveness in Multiple Sclerosis? A 7 Year-Retrospective Observational Study

Does Extended Interval Dosing Natalizumab Preserve Effectiveness in Multiple Sclerosis? A 7 Year-Retrospective Observational Study

The extended interval dosing (EID) of natalizumab has been suggested to be associated with a reduced risk of progressive multifocal leukoencephalopathy (PML) and short-term preservation of efficacy but its long-term effectiveness remain unknown. We aimed to determine the long-term effectiveness and...

Full description

Bibliographic Details
Main Authors: Javier Riancho, Sonia Setien, Jose Ramón Sánchez de la Torre, Marta Torres-Barquin, Mercedes Misiego, José Luis Pérez, Tamara Castillo-Triviño, Cristina Menéndez-García, Manuel Delgado-Alvarado
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Immunology
Subjects:
extended interval dosing
multiple sclerosis
natalizumab
disease modifying therapy
treatment
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.614715/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.614715/full

Similar Items